[{"NetIncomeLoss_1_Q1_USD":-45089000.0,"AccruedLiabilitiesCurrent_0_Q1_USD":20931000.0,"LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_0_Q1_USD":116254000.0,"AccumulatedOtherComprehensiveIncomeLossNetOfTax_0_Q1_USD":-260000.0,"RestrictedCashAndCashEquivalentsNoncurrent_0_Q1_USD":15227000.0,"FairValueLiabilitiesLevel2ToLevel1TransfersAmount_0_Q1_USD":0.0,"NetCashProvidedByUsedInInvestingActivities_1_Q1_USD":-471888000.0,"PaymentsToAcquireInvestments_1_Q1_USD":529907000.0,"LesseeOperatingLeaseLiabilityPaymentsDueYearThree_0_Q1_USD":13378000.0,"AssetsCurrent_0_Q1_USD":804316000.0,"CommitmentsAndContingencies_0_Q1_USD":null,"ContractWithCustomerAssetNetNoncurrent_0_Q1_USD":12883000.0,"StockIssuedDuringPeriodValueStockOptionsExercised_1_Q1_USD":5648000.0,"AccruedSalariesCurrent_0_Q1_USD":8373000.0,"LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_0_Q1_USD":12988000.0,"OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_1_Q1_USD":-330000.0,"CommonStockSharesIssued_0_Q1_shares":93888679.0,"Assets_0_Q1_USD":1045964000.0,"OperatingLeaseRightOfUseAsset_0_Q1_USD":67295000.0,"PreferredStockParOrStatedValuePerShare_0_Q1_USD":0.001,"CommonStockParOrStatedValuePerShare_0_Q1_USD":0.001,"AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_1_Q1_shares":25500000.0,"LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_0_Q1_USD":83159000.0,"WeightedAverageNumberOfShareOutstandingBasicAndDiluted_1_Q1_shares":93431877.0,"OperatingLeaseLiability_0_Q1_USD":110924000.0,"LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_0_Q1_USD":10274000.0,"ResearchAndDevelopmentExpense_1_Q1_USD":44852000.0,"LesseeOperatingLeaseLiabilityPaymentsDue_0_Q1_USD":194083000.0,"OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCreditLossesOnDebtSecuritiesHeld_0_Q1_USD":0.0,"LettersOfCreditOutstandingAmount_0_Q1_USD":15200000.0,"OtherNonoperatingIncomeExpense_1_Q1_USD":1121000.0,"AccountsReceivableNetCurrent_0_Q1_USD":6945000.0,"CommonStockValue_0_Q1_USD":94000.0,"IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_1_Q1_USD":6944000.0,"GeneralAndAdministrativeExpense_1_Q1_USD":12500000.0,"LesseeOperatingLeaseLiabilityPaymentsDueYearFive_0_Q1_USD":14193000.0,"NetCashProvidedByUsedInFinancingActivities_1_Q1_USD":438050000.0,"FairValueAssetsLevel2ToLevel1TransfersAmount_0_Q1_USD":0.0,"DebtSecuritiesAvailableForSaleRealizedGainLoss_1_Q1_USD":0.0,"OtherAssetsNoncurrent_0_Q1_USD":9000.0,"CashAndCashEquivalentsAtCarryingValue_0_Q1_USD":106413000.0,"OperatingLeaseLiabilityNoncurrent_0_Q1_USD":106512000.0,"ProceedsFromSaleMaturityAndCollectionsOfInvestments_1_Q1_USD":62000000.0,"CapitalizedContractCostAmortization_1_Q1_USD":623000.0,"OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_1_Q1_USD":-330000.0,"DepreciationDepletionAndAmortization_1_Q1_USD":959000.0,"IncreaseDecreaseInContractWithCustomerLiability_1_Q1_USD":-3107000.0,"LesseeOperatingLeaseLiabilityPaymentsDueYearFour_0_Q1_USD":13779000.0,"FairValueAssetsLevel1ToLevel2TransfersAmount_0_Q1_USD":0.0,"CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_1_Q1_USD":-60934000.0,"IncreaseDecreaseInAccountsReceivable_1_Q1_USD":1430000.0,"CommonStockSharesOutstanding_0_Q1_shares":93888679.0,"FairValueLiabilitiesLevel1ToLevel2TransfersAmount_0_Q1_USD":0.0,"RestrictedCashNoncurrent_0_Q1_USD":15227000.0,"AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_1_Q1_USD":12976000.0,"StraightLineRentAdjustments_1_Q1_USD":3534000.0,"NetCashProvidedByUsedInOperatingActivities_1_Q1_USD":-27096000.0,"LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_0_Q1_USD":13217000.0,"RetainedEarningsAccumulatedDeficit_0_Q1_USD":-602021000.0,"LiabilitiesCurrent_0_Q1_USD":94577000.0,"PrepaidExpenseAndOtherAssetsCurrent_0_Q1_USD":7236000.0,"ProceedsFromStockOptionsExercised_1_Q1_USD":5605000.0,"OtherAccruedLiabilitiesCurrent_0_Q1_USD":5744000.0,"OperatingLeaseWeightedAverageDiscountRatePercent_0_Q1_pure":0.084,"ShortTermLeaseCost_1_Q1_USD":0.0,"AdditionalPaidInCapital_0_Q1_USD":1392279000.0,"CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_0_Q1_USD":121640000.0,"CapitalExpendituresIncurredButNotYetPaid_1_Q1_USD":2624000.0,"PropertyPlantAndEquipmentNet_0_Q1_USD":47950000.0,"AccountsPayableCurrent_0_Q1_USD":8998000.0,"IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_1_Q1_USD":1301000.0,"VariableLeaseCost_1_Q1_USD":235000.0,"LongTermInvestments_0_Q1_USD":98284000.0,"CommonStockSharesAuthorized_0_Q1_shares":150000000.0,"RevenueFromContractWithCustomerExcludingAssessedTax_1_Q1_USD":11142000.0,"OperatingIncomeLoss_1_Q1_USD":-46210000.0,"OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale_1_Q1_USD":0.0,"InvestmentIncomeInterest_1_Q1_USD":377000.0,"ContractWithCustomerLiabilityCurrent_0_Q1_USD":21033000.0,"PreferredStockValue_0_Q1_USD":3000.0,"OperatingLeaseCost_1_Q1_USD":3769000.0,"LiabilitiesAndStockholdersEquity_0_Q1_USD":1045964000.0,"AccretionAmortizationOfDiscountsAndPremiumsInvestments_1_Q1_USD":-1140000.0,"PreferredStockSharesAuthorized_0_Q1_shares":5000000.0,"SharePrice_0_Q1_USD":82.45,"OperatingLeaseLiabilityCurrent_0_Q1_USD":4412000.0,"OperatingExpenses_1_Q1_USD":57352000.0,"RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_1_Q1_USD":1444000.0,"EarningsPerShareBasicAndDiluted_1_Q1_USD":-0.48,"ProfitLoss_1_Q1_USD":-45089000.0,"StockholdersEquity_0_Q1_USD":790095000.0,"ContractWithCustomerLiabilityNoncurrent_0_Q1_USD":43025000.0,"PaymentsToAcquirePropertyPlantAndEquipment_1_Q1_USD":3981000.0,"AllocatedShareBasedCompensationExpense_1_Q1_USD":12976000.0,"ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_1_Q1_USD":-45419000.0,"Ticker":"FATE","CIK":"1434316","name":"FATE THERAPEUTICS INC","OfficialName":"Fate Therapeutics Inc. Common Stock","form":"10-Q","period":"20210331","fy":"2021.0","fp":"Q1","qtrs":"1","uom":"USD","footnote":"nan","Market Cap":"3545646272.0","Country":"United States","Sector":"Health Care","Industry":"Biotechnology: Biological Products (No Diagnostic Substances)","Market":"NASDAQ","SP500":"nan","filed":"20210505"}]